Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation

• Váldodahkkit: Dusan Ruzic (Dahkki), Bernhard Ellinger (Dahkki), Nemanja Djokovic (Dahkki), Juan F. Santibanez (Dahkki), Sheraz Gul (Dahkki), Milan Beljkas (Dahkki), Ana Djuric (Dahkki), Arasu Ganesan (Dahkki), Aleksandar Pavic (Dahkki), Tatjana Srdic-Rajic (Dahkki), Milos Petkovic (Dahkki), Katarina Nikolic (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2022-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Isoform-selective histone deacetylase (HDAC) inhibition is promoted as a rational strategy to develop safer anti-cancer drugs compared to non-selective HDAC inhibitors. Despite this presumed benefit, considerably more non-selective HDAC inhibitors have undergone clinical trials. In this report, we d...